Reported Earlier, Royalty Pharma Announced An Update On Novartis’ Phase 3 Results From The Horizon Outcomes Trial For Pelacarsen, An Antisense Oligonucleotide Studied In Patients With Atherosclerotic Cardiovascular Disease And Elevated Lipoprotein(A)

뉴스 본문을 불러오고 있어요.

Reported Earlier, Royalty Pharma Announced An Update On Novartis’ Phase 3 Results From The Horizon Outcomes Trial For Pelacarsen, An Antisense Oligonucleotide Studied In Patients With Atherosclerotic Cardiovascular Disease And Elevated Lipoprotein(A) | 웨이프 WAPE

Reported Earlier, Royalty Pharma Announced An Update On Novartis’ Phase 3 Results From The Horizon Outcomes Trial For Pelacarsen, An Antisense Oligonucleotide Studied In Patients With Atherosclerotic Cardiovascular Disease And Elevated Lipoprotein(A)

기사 요약

관련 종목

댓글 —